CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing
Mar 28, 2017 12:01 pm UTC| Business
- Patent to include CRISPR/Cas9 gene editing compositions for use in any non-cellular and cellular setting, including human and other eukaryotic cells BASEL, Switzerland, March 28, 2017 -- CRISPR Therapeutics...
CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing
Mar 28, 2017 12:01 pm UTC| Business
- Patent to include CRISPR/Cas9 gene editing compositions for use in any non-cellular and cellular setting, including human and other eukaryotic cells BASEL, Switzerland, March 28, 2017 -- CRISPR Therapeutics...
Alder BioPharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
Mar 28, 2017 12:01 pm UTC| Business
BOTHELL, Wash., March 28, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its...
Alder BioPharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
Mar 28, 2017 12:01 pm UTC| Business
BOTHELL, Wash., March 28, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its...
AMAG Pharmaceuticals to Present at the Needham Healthcare Conference
Mar 28, 2017 12:01 pm UTC| Business
WALTHAM, Mass., March 28, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET. A...
AMAG Pharmaceuticals to Present at the Needham Healthcare Conference
Mar 28, 2017 12:01 pm UTC| Business
WALTHAM, Mass., March 28, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 4:20 p.m. ET. A...
Fibrocell Regains Compliance with NASDAQ Listing Requirements
Mar 28, 2017 12:01 pm UTC| Business
EXTON, Pa., March 28, 2017 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it...